Company news
Merck & Company, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
VIPC Signs MOU with AstraZeneca, Eli Lilly, Merck to Develop the Virginia Center for Advanced Pharmaceutical Manufacturing to Train Workforce of the Future
November 20, 2025
Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WINREVAIR® (sotatercept)
November 20, 2025
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection
November 19, 2025
European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union
November 19, 2025
Merck Announces First-Quarter 2026 Dividend
November 18, 2025
Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)
November 18, 2025
Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent
November 14, 2025
Merck to Participate in the Jefferies Global Healthcare Conference in London
November 13, 2025
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial
November 9, 2025
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
November 8, 2025
Codexis Reports Third Quarter 2025 Financial Results
November 6, 2025
Alliance for Building Better Medicine and the Virginia Innovation Partnership Celebrate $120 Million Investment from AstraZeneca, Eli Lilly, and Merck to Advance Virginia's Advanced Pharmaceutical Manufacturing Workforce
November 5, 2025
Quebec Expands Public Funding for CAPVAXIVE®
November 5, 2025
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
November 4, 2025
Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
November 4, 2025
Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.
November 3, 2025
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results
October 30, 2025
Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
October 29, 2025
European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)
October 29, 2025
Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy
October 28, 2025
Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
October 28, 2025
U.S. FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH Study
October 27, 2025
Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025
October 23, 2025
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer
October 23, 2025
Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer
October 21, 2025
Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults
October 21, 2025
KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)
October 20, 2025
Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia
October 20, 2025
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
October 19, 2025
KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer
October 18, 2025
Calls
The 5 newest of 32 calls. Every call is listed under its year.
- Merck & (NYSE:MRK) Q3 2026 Earnings Call
Oct 29, 2026
Transcript - Merck & (NYSE:MRK) Q2 2026 Earnings Call
Aug 4, 2026
Transcript - Merck & (NYSE:MRK) Q1 2026 Earnings Call
Apr 30, 2026
Transcript - Merck & (NYSE:MRK) Q4 2025 Earnings Call
Feb 3, 2026
Transcript - Merck & (NYSE:MRK) Q3 2025 Earnings Call
Oct 30, 2025
Transcript
Decks
The 5 newest of 99 decks. Every deck is listed under its year.
- Q3 2026 Earnings Presentation
Earnings · 28 slides · Oct 29, 2026
- Investor Day (October 2026)
Investor day · 27 slides · Oct 26, 2026
- Q2 2026 Earnings Presentation
Earnings · 33 slides · Aug 4, 2026
- International AIDS Conference (AIDS 2026) Investor Event
Conference · 34 slides · Aug 3, 2026
- Investor Day (June 2026)
Investor day · 39 slides · Jun 1, 2026